Introduction
Methods
Results
Mitotic rate
Reference | AGCT/JGCT | Cases (n) | Stage | MI Cut off | Prognostic Significance |
---|---|---|---|---|---|
Malmström 1994 [14] | Not specified | n = 54; assessment of MI in n = 42 | I (83%); II (11%); III (2%) | ≤4 HPF; 5–9 HPF; ≥10 HPF | Survival reduced in subgroup, no p-value given |
King 1996 [15] | n = 38 AGCT; n = 2 JGCT | n = 40 | I (77.5%); II (7.5%); III (15%) | Not specified | Stage (p = 0.005) Survival (p = 0.006) |
Fujimoto 2001 [16] | AGCT | n = 27 | I (63%); II (15%); III (19%); IV (3%) | 4/10 HPF | Survival (p < 0.005) Recurrence (p < 0.001) |
Sehouli 2004 [9] | Not specified | n = 65 | I (80%); II (7.7%); III (9.2%); IV (3.1%) | 5/10 HPF | Survival (p < 0.001) |
Van Meurs 2014 [17] | AGCT | n = 127 | I (76%); II-IV (24%) | 5/10 HPF | Recurrence (p < 0.001) |
Thomakos 2016 [18] | AGCT | n = 43 | I (95%); II (5%) | 4/10 HPF | Recurrence (p = 0.027) |
Sakr 2017 [19] | n = 113 AGCT n = 12 JGCT | n = 125 | I-II (95%); III-IV (5%) | 4/10 HPF | Recurrence (p = 0.021) DFI (p = 0.005) |
Dridi 2018 [20] | AGCT | n = 31; assessment of MI in n = 22 | I (61%); II (10%); III (19%); IV (10%) | Not specified | Survival (p = 0.01) |
Costa 1995 [21] | n = 49 AGCT n = 7 JGCT | n = 56 | I (84%); II (3%): III (13%) | 5/10 HPF | No significance |
Lauszus 2001 [22] | Not specified | n = 37 | I (100%) | Not specified | No significance |
Lin 2005 [23] | AGCT | n = 36 | I (97%); II (3%) | < 1 HPF; 2–3 HPF ≥4 HPF | No significance |
Kim 2006 [24] | AGCT | n = 35 | I (86%); II (3%); III (11%) | Not specified | No significance |
Pectasides 2008 [25] | AGCT | n = 34 | I (59%); II (8%); III (22%); IV (11%) | 1–3 HPF; 4–10 HPF; > 10 HPF | No significance |
Leuverink 2008 [27] | AGCT | n = 38 | I (76%); II (11%); III (11%); IV (2%) | Not specified | No significance |
Suri 2013 [26] | AGCT | n = 104; assessment of MI in n = 50 | I (95%); II (1%); III (4%) | 4/10 HPF | No significance |
Ki-67
p53
CD56
Estrogen receptor
Inhibin
Anti-Mullerian hormone (AMH)
E-cadherin, ß-catenin
GATA-4
HER2
FOXL2
SMAD3 (mothers against decapentaplegic homolog 3)
Discussion
Marker | Number of references reviewed in article | Conclusion | Notes |
---|---|---|---|
Anti-Mullerian hormone (AMH) | n = 1 | Prognostic significance unclear | - Correlation of AMH expression with larger tumor size, but not with prognostic data |
CD56 | n = 3 | Prognostic significance | - High IHC expression associated with increased recurrence and decreased DFI |
E-cadherin, β-Catenin | n = 3 | Prognostic significance unclear | - conflicting data on expression and prognostic validity |
Estrogen | n = 4 | No prognostic significance | - Studies with conflicting results |
FOXL2 | n = 3 | Prognostic significance | - FOXL2 expression is associated with decreased DFS and OS in JGCT - FOXL2 mutation and FOXL2 mRNA are associated with reduced DFS in AGCT |
GATA-4 | n = 3 | Prognostic significance | - High expression of GATA-4 is associated with reduced DFS, higher tumor stage and recurrence |
HER2 | n = 8 | Prognostic significance unclear | - conflicting data on IHC expression of HER2 |
Inhibin | n = 5 | No prognostic significance | - Studies with significant and insignificant results |
Ki-67 | n = 6 | Prognostic significance unclear | - Studies with significant and insignificant results - variations, e.g. inter-observer variation not considered in most studies |
Mitotic rate | n = 15 | Prognostic significance unclear | - Studies with significant and insignificant results - different cut-off values - different microscopes and field diameters - currently counted in mm2 |
p53 | n = 10 | Prognostic significance unclear | - conflicting results of p53 IHC expression - interpretation problems regarding p53 IHC as mutation-positive |
SMAD3 | n = 1 | Prognostic significance | - High expression of SMAD3 is associated with increased recurrence and shorter DFI |